The Lankenau Institute for Medical Research

Current Clinical Trials

Listed below you will find clinical trials that are taking place at LIMR. Additionally, Main Line Health has various clinical trials through the Community Clinical Oncology Program (CCOP) and the Heart Center. For further general infomation about clinical trials please contact LIMR's Clinical Research Center at 484-476-3343.

ENGAGE AF TIMI 48 (Effective aNticoaGulation with xA next Generatuion in Atrial Fibrillation) A Phase III, Randomized, Double-Blind, Double-Dummy, Parallel Group, Multicenter, Multinational Study for the Evaluation of Efficacy and Safety of DU-176B versus Warfarin in Subjects with Atrial Fibrillation

DESCRIPTION:

Patients with atrial fibrillation who require long term anticoagulation (blood thinning) to prevent strokes and blood clots may be eligible for this study which compares a new anticoagulant (blood thinner) with warfarin.

STATUS:

Open to accrual.

LIMR/MLH INVESTIGATOR:

Michael D. Ezekowitz, MD, PhD

SPONSOR:

Daiichi Sankyo Pharmaceuticals

CONTACT:

ENGAGE Study Team - 484.476.3343 or CRC@mlhs.org

Download ENGAGE Brochure

RELY-ABLE -Extension to the RE-LY Study

DESCRIPTION:

RE-LY participants were individuals with atrial fibrillation who require long term anti-coagulation. The only eligible patients for RELY-ABLE are those who participated in RE-LYand were assigned to receive dabigatran.

STATUS:

Closed to accrual. This study is no longer accepting new patients.

LIMR/MLH INVESTIGATOR:

Michael D. Ezekowitz, MD, PhD

SPONSOR:

Boehringer-Ingelheim Pharmaceuticals

CONTACT:

RELY-ABLE Study Team - 484.476.3343 or CRC@mlhs.org

A Phase 0, Open Label, Non-Randomized, Multicenter, Exploratory, and Safety Study of [F-18]W372

DESCRIPTION:

Patients with early Alzheimer's Disease may be eligible to participate in this study of a new drug for use in future studies of brain imaging in early Alzheimer's Disease.